A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer
- 15 July 1982
Abstract
Twenty‐five patients with metastatic prostate cancer were treated with a combination of Adriamycin 50 mg/m2 and cis‐platinum (CDDP) 50 mg/m2 every three weeks. Response was evaluated using radioisotope bone scan, serum acid phosphatase levels, and clinical status. Response rates of 6% bone, 21% acid phosphatase, and 24% clinical status were noted. Major toxicity was gastrointestinal (due to CDDP). Treatment was well tolerated even in patients with extensive bone metastases and prior irradiation. Using the response criteria described here, patients with metastatic prostate cancer without measurable soft tissue disease are eligible for Phase II and III study.This publication has 19 references indexed in Scilit:
- A critical analysis of response criteria in patients with prostatic cancer treated with CIS-diamminedichloride platinum IICancer, 1979
- Comparison of Procarbazine, Imidazole-Carboxamide and Cyclophosphamide in Relapsing Patients with Advanced Carcinoma of the ProstateJournal of Urology, 1979
- Treatment of Advanced Carcinoma of the Prostate (Stage D) with Infusion of CIS-Diamminedichloroplatinum (II NSC 119875): A Pilot StudyJournal of Urology, 1978
- Chemotherapy trial with comp-F regimen in advanced adenocarcinoma of prostateUrology, 1978
- A Comparison of Estramustine Phosphate and Streptozotocin in Patients with Advanced Prostatic Carcinoma Who Have Had Extensive IrradiationJournal of Urology, 1977
- Dose response evaluation of adriamycin in human neoplasiaCancer, 1977
- Multiple Drug Chemotheraphy Regimen for Patient with Hormonnally-Unresponsive carcinoma of the Prostate: A Preliminary ReportJournal of Urology, 1977
- The Continued Evaluation of the Effects of Chemotherapy in Patients with Advanced Carcinoma of the ProstateJournal of Urology, 1976
- Chemotherapy of Advanced Carcinoma of the Prostate with 5-Fluorouracil, Cyclophosphamide and AdriamycinJournal of Urology, 1976
- Mithramycin and Metastatic Carcinoma of the ProstateJournal of Urology, 1970